BioSpace News Archive

The MagMAX Viral/Pathogen Ultra Nucleic Acid Isolation Kit is a new automation-ready kit for scalable recovery of RNA and DNA from difficult to lyse microorganisms

GIBCO CTS LV-MAX Lentiviral Production System is a complete lentivirus production solution designed to produce high titer lentiviral vectors. This is the first optimized LV vector production system in suspension culture designed to meet USP <1043> standards.

VUCA Health announced that Kalos, a provider of software solutions to retail pharmacies and universities, will integrate VUCA Health’s digital patient education solution, MedsOnCue, with their ProPharmOne™ software.

PetaGene, the genomics data compression and acceleration company has been awarded “Best of Show” at the 2019 Bio-IT World Conference & Expo.

NervGen Pharma Corp.(“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPσ) targeted therapies for heart diseases and injury, and for root avulsion involving injuries into the peripheral nerve system.

Novo Nordisk announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza® injection 1.8 mg vs placebo in reducing blood sugar in children and adolescents aged 10-17 with type 2 diabetes.1 ELLIPSE is the first phase 3 trial completed in over a decade in children and adolescents with type 2 diabetes.

Chinese registrational clinical trial for derazantinib to begin in 2H 2019

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye.

The Nestlé Skin Health SHIELD Skin Microbiome Summit in New York showcased the rapid research developments which have been advancing in recent years.

Pacific Biosciences of California Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the commercial launch of the Sequel® II System.